Literature DB >> 8536854

Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection.

D Prati1, C Capelli, A Zanella, F Mozzi, P Bosoni, M Pappalettera, F Zanuso, L Vianello, E Locatelli, C de Fazio, G Ronchi, E del Ninno, M Colombo, G Sirchia.   

Abstract

BACKGROUND & AIMS: The association of liver disease with hepatitis C virus (HCV) genotypes mainly refers to patients with serious liver damage; little information is available on symptomless carriers. The aim of this study was to investigate the correlation of genotypes with clinical course, risk factors for infection, and antibody to HCV reactivity in asymptomatic subjects.
METHODS: One hundred nine viremic blood donors with at least 1 year of follow-up were studied; 41 underwent liver biopsy. Genotypes were determined by line-probe assay.
RESULTS: Genotype 1 was found in 47 (43.1%), genotype 2 in 48 (44%), genotype 3 in 8 (7.3%), genotype 4 in 2 (1.8%), and coinfections in 4 (3.7%). The relative risk (RR) for a raised pattern of alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyltranspeptidase was 2.1 (confidence interval [CI], 1.4-3.2), 1.7 (CI, 1.2-2.4), and 2.8 (CI, 1.6-4.9) in subjects with genotype 1 vs. 0.4 (CI, 0.2-0.7), 0.4 (CI, 0.3-0.7), and 0.4 (CI, 0.2-0.8) in subjects with genotype 2. Chronic hepatitis was found in 68%; the RR of chronic hepatitis was similar for genotypes 1 and 2 (RR, 1.1 [CI, 0.8-1.7] vs. RR, 1.0 [CI, 0.7-1.6]). Reactivity to NS4-derived antigens was infrequent in type 2-infected subjects.
CONCLUSIONS: Genotype 2 was as frequent as genotype 1 but associated with less liver function impairment. The high prevalence of chronic hepatitis should be considered in counseling viremic asymptomatic donors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8536854     DOI: 10.1053/gast.1996.v110.pm8536854

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study.

Authors:  A R Osella; L Sonzogni; A Cavallini; L Foti; V Guerra; A Di Leo; M U Mondelli; G Misciagna; E M Silini
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Clinical relevance of hepatitis C virus genotypes.

Authors:  P Simmonds
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma.

Authors:  Adriano M Pellicelli; Massimo Marignani; Valerio Zoli; Mario Romano; Aldo Morrone; Lorenzo Nosotti; Giuseppe Barbaro; Antonio Picardi; Umberto Vespasiani Gentilucci; Daniele Remotti; Cecilia D'Ambrosio; Caterina Furlan; Fabrizio Mecenate; Ettore Mazzoni; Ignazio Majolino; Roberto Villani; Arnaldo Andreoli; Giorgio Barbarini
Journal:  World J Hepatol       Date:  2011-11-27

4.  Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico city.

Authors:  Nahum Méndez-Sánchez; Guadalupe Ponciano-Rodriguez; Norberto C Chávez-Tapia; Daniel Motola-Kuba; Paloma Almeda-Valdes; Karla Sánchez-Lara; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

5.  Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; R Laufs
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study.

Authors:  S Bellentani; G Pozzato; G Saccoccio; M Crovatto; L S Crocè; L Mazzoran; F Masutti; G Cristianini; C Tiribelli
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

7.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease.

Authors:  C M da Silva; F L David; M N Muscará; S S Sousa; J G Ferraz; G de Nucci; N C Polimeno; J Pedrazzoli
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features.

Authors:  L De Moliner; P Pontisso; G L De Salvo; L Cavalletto; L Chemello; A Alberti
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

Review 10.  Hepatitis C virus-related lymphoproliferative disorders: an overview.

Authors:  Anna-Linda Zignego; Carlo Giannini; Clodoveo Ferri
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.